Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema
Study Details
Study Description
Brief Summary
Specific treatments for angiotensin-converting-enzyme inhibitor (ACE-I) and angiotensin-receptor-blocker (ARB)-induced angioedema exist. Early access to these treatments is challenging because they are expensive and have short shelf lives making it illusory that all emergency department (ED) stock them. The aim of this retrospective study was to define, for each patient with a confirmed ACE-I or ARB-induced angioedema, at which step of the care, the specific treatment was administered. The second objective was to analyse the availability of these treatment in the area around Lyon, France and the factors that may influence it.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Step of the care allowing the patients to benefit from a specific treatment. [October 2010 to December 2014]
Three answers are possible. Patients were treated with the specific medication (icatibant or C1-inhibitor concentrate) either in the first ED or by the medical ambulance team, or by the investigators reference center's intensive care unit.
Secondary Outcome Measures
- Epidemiological characteristics [October 2010 to December 2014]
The investigators collect data such as age, sex, localization of the angioedema.
- Triggering treatments [October 2010 to December 2014]
The investigators detail which ACE-inhibitor, which ARB and eventually which co-medication was taken and triggered the angioedema.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Every patient followed for the first time in our reference center for severe confirmed ACE-I or ARB-induced angioedema. Data were analyzed from patients attended either in a specialized angioedema consultation or during a hospitalization in our intensive care unit.
-
Severe attack was defined either by its localization over the shoulder or by an severe abdominal attack.
Exclusion Criteria:
- Patients which received no specific treatment (icatibant, C1-inhibitor concentrate) were excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospices Civils de Lyon, Département d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Lyon, France. | Lyon | France | 69003 |
Sponsors and Collaborators
- Hospices Civils de Lyon
Investigators
- Principal Investigator: Bernard FLOCCARD, MD, Hospices Civils de Lyon, Département d'Anesthésie-Réanimation, Hôpital Edouard Herriot, Lyon, France.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 69HCL16_0430